Sales and Distribution Collaboration of ISODINE(R) Brand

SINGAPORE, Dec. 9, 2015 /PRNewswire/ -- Mundipharma K.K. and Shionogi & Co., Ltd. today announced a new exclusive sales collaboration contract for its ISODINE^® brand in Japan. Under the contract, Shionogi will exclusively sell and distribute ISODINE^® OTC products. This new contract succeeds the relationship with former partner Meiji Seika Pharma Co., Ltd.

Following this agreement, Mundipharma K.K. retains the rights to the items listed below. These items will be sold and distributed in Japan by a new company "Shionogi Healthcare" (begin business from April 1^st, 2016) responsible for Shionogi's consumer health business.

In addition, a basic agreement with Shionogi to sell and distribute ISODINE^® brand ethical products has been reached. The details of the agreement will be disclosed subsequently.

"Mundipharma has been offering povidone-iodine preparations on overseas markets for over 5 decades and ISODINE^® known in other markets as Betadine^®, is currently sold in 30 countries worldwide," said Shosuke Kimura, President and Representative Director of Mundipharma. On the partnership with Shionogi, he added: "We expect Shionogi's experience in infectious disease prevention, which complements our own, will realize further contribution to infection control measures."  

Isao Teshirogi, President & CEO of Shionogi said: "Shionogi has a history of conducting the research, development and sales of innovative anti-infective agents for over 50 years.  Positioning 'infectious disease' as the priority disease area, we have been contributing to the treatment of infectious disease with our wide-ranged product lines including therapeutic agents for HIV or influenza virus infection for medical use, antibacterial agents, non-prescription antipyretic analgesics and general cold drugs. This sales collaboration for ISODINE^® brand products allows us to offer products from prevention to treatment of infectious disease consistently and we are expecting to realize further contribution to the improvement of the quality of life (QOL) of patients and customers."

Notes

1. A list of items subjected to the sales collaboration
OTC drugs: Isodine^® Ugaigusuri, Isodine^®® Ugaigusuri P, Isodine^® Ugaigusuri C, Isodine^® Nodo Fresh F, Isodine^® Wash, Isodine^® Vulnerary and Isodine^® Nankou

2. Scheduled commencement day of sales collaboration
OTC drugs: March 31, 2016

®:  ISODINE^® and BETADINE^® are Registered Trademarks.

About ISODINE^®

ISODINE^® brand includes solution and semisolid (ointment, gel and cream) types of OTC drugs, ethical pharmaceuticals and veterinary drugs containing PVP-I (povidone-iodine), a disinfection component developed by Mundipharma.  In Japan, it was launched as a disinfectant in 1961, following the licensing from Mundipharma B.V. to Meiji Seika Kaisha, Ltd. (currently, Meiji Seika Pharma Co., Ltd.).

About Mundipharma K.K.

Established in Japan in 1991, Mundipharma K.K. acts to become the best partner for medical care by contributing to the improvement of patients' QOL with three main pillars of business: Pain, Cancer and Consumer Healthcare and is planning for further fulfilling of our pipelines and expansion of our business. For details, please visit our homepage at http://mundipharma.co.jp.

About Shionogi & Co., Ltd.

Shionogi, based on its Company Policy to "supply the best possible medicine to protect the health and wellbeing of the patients we serve", is focused on offering the best medicine to patients worldwide as a pharmaceutical company to research and develop drugs. Positioning infectious disease and the fields of pain and nerve as the priority disease areas for research and development, we also work on new disease areas including obesity, senescent metabolic disease, tumor and immunological disease. Shionogi is to continue to contribute to health and the improvement of QOL of people all over the world by offering innovative drugs in those disease areas.  For details, please visit our homepage at http://www.shionogi.co.jp.

Media Contact:

Stephenie Vasko
Communications Director - Asia Pacific, Latin America, Middle East and Africa
TEL: +65-6303-9732
stephenie.vasko@mundipharma.com.sg
http://www.mundipharma.com.sg

Public Relations Office,
Mundipharma K.K.
Tokyo, TEL: +81 (0) 3-6718-2937

Public Relations Department,
Shionogi & Co., Ltd.
Osaka: TEL: +81 (0) 6-6209-7885  FAX: +81 (0) 6-6229-9596
Tokyo: TEL: +81 (0) 3-3406-8164  FAX: +81 (0) 3-3406-8099

Logo - http://photos.prnasia.com/prnh/20151209/8521508446